TAPIMMUNE INC | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (40)

View All

Latest Posts

About This Stock More About This Stock
ARWR Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi; TPIV Announces Phase II Clinical Trials With VGTI Florida
Article By: BioMedReports
Wednesday, November 19, 2014 3:29 AM EDT
ARWR today announced that it recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate.TPIV. is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida.
In this article: TPIV, ARWR
Read
TapImmune Shares Gain 28% On Pending Catalysts And Published Comments By CEO
Article By: BioMedReports
Tuesday, November 18, 2014 5:37 AM EDT
Shares of TapImmune, Inc. rose nearly 30% after the firm was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, PH.D.
In this article: TPIV
Read
Biotech Stocks: The Sector's Most Comprehensive Immunotherapy Platforms
Article By: BioMedReports
Friday, November 7, 2014 4:58 AM EDT
The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
In this article: INO, NWBO, TPIV, DNDN, GALE
Read
Biotech Investors Gamble On Ebola Stocks
Article By: BioMedReports
Tuesday, October 7, 2014 6:39 AM EDT
The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA’s awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more than constant media attention.
In this article: HEB, INO, TPIV, TKMR
Read
“New Frontier Stocks” At Play In The Battle Against Ebola
Article By: M.E. Garza
Sunday, October 5, 2014 10:34 AM EDT
Several public companies have thrown their hats into the Ebola pandemic conversation, but only some will perform well for investors day in and day out.
In this article: HEB, INO, TPIV, TKMR
Read
All Posts

Latest Tweets for $TPIV

No tweets yet!

PARTNER HEADLINES